WhaleCreep

Casdin Capital, LLC 13F holdings, Q1 2020

Hedge fundSEC filingsCompare with another fundHoldings as of 2020-03-31, filed 2020-05-15

Casdin Capital, LLC disclosed 38 US equity positions worth $942.0m in its Q1 2020 13F filing. Its largest position is 2655787D at 9.6% of the reported book, followed by SRPT and ALNY. Versus Q4 2019 it opened 8 new positions, added to 12, reduced 8 and exited 1.

$942m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
38
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
9.6%
Largest position
The largest single position as a share of the reported equity book.
58.1%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
22
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2019: 8 new, 12 added, 8 reduced, 1 exited

38 rows
2655787D BLUEPRINT MEDICINES CORP–9.6%$90.6m1.55m+65%added
SRPT SAREPTA THERAPEUTICS INCHealthcare7.0%$65.5m670,0000.0%held
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare6.8%$63.7m585,000+14%added
FATE FATE THERAPEUTICS INCHealthcare6.0%$56.6m2.55m0.0%held
CDXS CODEXIS INCHealthcare6.0%$56.6m5.07m0.0%held
BLUEBIRD BIO INC no ticker–5.4%$50.8m1.10m+14%added
NVTA1EUR INVITAE CORP–5.0%$47.5m3.48m−4.4%reduced
MYOKEUR MYOKARDIA INC–5.0%$46.6m995,000−1.0%reduced
AGIO AGIOS PHARMACEUTICALS INCHealthcare4.0%$38.0m1.07m+30%added
CNST CONSTELLATION PHARMCETICLS I–3.3%$30.8m980,000−19%reduced
TWST TWIST BIOSCIENCE CORPHealthcare3.2%$30.6m1.00m+233%added
RVMD REVOLUTION MEDICINES INCHealthcare3.1%$28.9m1.32m–new
CDNA CAREDX INCHealthcare3.0%$28.3m1.29m+7.9%added
ALEC ALECTOR INCHealthcare2.8%$26.0m1.08m0.0%held
DNLI DENALI THERAPEUTICS INCHealthcare2.7%$25.5m1.46m+16%added
BLFS BIOLIFE SOLUTIONS INCHealthcare2.5%$23.5m2.47m0.0%held
ADPT ADAPTIVE BIOTECHNOLOGIES CORHealthcare2.3%$22.0m793,125+71%added
MAGENTA THERAPEUTICS INC no ticker–2.0%$18.7m2.97m−4.1%reduced
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–1.6%$15.3m300,0000.0%held
FULC FULCRUM THERAPEUTICS INCHealthcare1.5%$14.4m1.21m−2.4%reduced
GNMK GENMARK DIAGNOSTICS INC–1.5%$13.9m3.37m0.0%held
2JQ GRITSTONE BIO INC–1.4%$13.2m2.27m+5.1%added
GILD GILEAD SCIENCES INCHealthcare1.4%$13.1m175,000–new
CRSP CRISPR THERAPEUTICS AGHealthcare1.2%$11.3m266,430–new
SG7 SAGE THERAPEUTICS INC–1.2%$11.1m385,000+67%added
ADVMCHF ADVERUM BIOTECHNOLOGIES INC–1.2%$11.0m1.13m–new
VYGR VOYAGER THERAPEUTICS INCHealthcare1.1%$10.0m1.10m0.0%held
ZLAB ZAI LAB LTDHealthcare1.0%$9.8m190,000–new
ALLO ALLOGENE THERAPEUTICS INCHealthcare1.0%$9.7m500,000–new
BRISTOL-MYERS SQUIBB CO no ticker–1.0%$9.5m2.50m+67%added
SGMOQ SANGAMO THERAPEUTICS INCHealthcare1.0%$9.3m1.46m0.0%held
ILMN ILLUMINA INCHealthcare0.9%$8.2m30,000−50%reduced
ORTXUSD ORCHARD THERAPEUTICS PLC–0.8%$7.3m975,000+19%added
BDTX BLACK DIAMOND THERAPEUTICS IHealthcare0.8%$7.2m289,395–new
DCPHEUR DECIPHERA PHARMACEUTICALS IN–0.6%$5.8m140,000−45%reduced
DMTKQ DERMTECH INC–0.6%$5.6m571,713–new
TURNING POINT THERAPEUTICS I no ticker–0.4%$3.4m75,0000.0%held
STOK STOKE THERAPEUTICS INCHealthcare0.3%$2.7m120,000−7.7%reduced

Exited since Q4 2019

1 row
BOLDEUR AUDENTES THERAPEUTICS INC4.8%$51.5m

Sector mix

  • Healthcare59.5%
  • Unclassified40.5%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters